Abstract: TH-PO941
The Effectiveness of mRNA COVID-19 Vaccine Against SARS-CoV-2 Infection in Hemodialysis Patients: A Case-Control Study
Session Information
- COVID-19: Vaccines and Outcomes ESRD/KTR
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Hamad, Abdullah Ibrahim, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Elshirbeny, Mostafa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Ali, Mohamed Yousif Mohamed Salih, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Ghonimi, Tarek Abdellatif, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Ibrahim, Rania Abdelaziz, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Yasin, Fadumo Yusuf, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Singh, Poonam Ravinder, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Aly, Sahar, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Abuhelaiqa, Essa, Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Al-Malki, Hassan A., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
- Alkadi, Mohamad M., Hamad Medical Corporation, Doha, Ad Dawhah, Qatar
Background
Hemodialysis (HD) patients are at higher risk for SARS-CoV-2 infection and its severe complications compared to the general population. Several studies examined the effectiveness of COVID-19 vaccines in this highly vulnerable population but showed mixed results. The aim of this study was to determine the effectiveness of mRNA vaccines against confirmed SARS-CoV-2 infection in HD patients in the State of Qatar.
Methods
We used a test-negative case-control design to determine the effectiveness of vaccination in HD patients > 14 days after the second dose. Ninety-five patients had positive SARS-CoV-2 PCR (cases), while 884 patients had negative PCR (controls). Vaccine effectiveness was determined using the following formula [Vaccine effectiveness = 1 – Odds (T+ |vaccinated) /Odds (T+|non-vaccinated)].
Results
Thirty out of 691 vaccinated HD patients had positive SARS-CoV-2 PCR versus 65 out of 288 non-vaccinated patients (4% vs. 23%, P<0.0001). Patients were more likely to have positive PCR if they were females (P<0.0001), elderly (P=0.02), or Asians (P=0.03). The overall effectiveness of mRNA COVID-19 vaccines against confirmed SARS-CoV-2 infection was 84.5% (95% CI: 76.5-89.8; Table 1)
Conclusion
Our data support the importance of using the mRNA COVID-19 vaccine in HD patients to prevent SARS-CoV-2 infection in such a high-risk population.
Table 1: Vaccine Effectiveness against confirmed infection
| Vaccine type | Positive SARS-CoV-2 | Negative SARS-CoV-2 | Adjusted vaccine effectiveness, % | (95% CI) |
| mRNA-1273 (Moderna) | 1 | 68 | 94.9 | (79.7 to 99.8) |
| BNT-162b2 (Pfizer) | 29 | 593 | 83.3 | (74.4 to 89.1) |
| All vaccinated | 30 | 661 | 84.5 | (76.5 to 89.8) |
| Non-vaccinated | 65 | 223 | Reference | Reference |